Your session is about to expire
← Back to Search
DF9001 + Nivolumab for Solid Tumors
Study Summary
This trial will test a new molecule to target cancer cells and enhance cancer-fighting NK/T-cells. It has two phases, testing in patients with solid tumors. A combo therapy will be used.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have received an organ or stem cell transplant.My liver is working well.My cancer has worsened despite treatment for its advanced stage.My colorectal cancer has returned or spread and tests show it has EGFR expression.My cancer is not known to be MMR/MSI high.My cancer progressed after treatment with anti-PD-(L)1 therapy.I do not have significant infections like HIV or active hepatitis.I have a medical history that may increase my risk of side effects from EGFR treatment.I haven't had chemotherapy, major surgery, or experimental drugs within the last 28 days.I have had or currently have inflammation or damage to my cornea.My blood counts are within a healthy range.I do not have severe heart issues, uncontrolled high blood pressure, or serious lung problems.My advanced cancer has EGFR expression and standard treatments have failed.My kidney function is normal.I've had one round of specific chemotherapy for my cancer and, if my cancer is RAS wild-type, I've also had an anti-EGFR antibody treatment.I am mostly active and my doctor expects me to live at least 3 more months.I had a heart or lung stoppage due to a temporary cause that's now gone.I haven't needed strong immune system medications for a long condition, except for stable hormone treatments.I have severe allergies to certain medications or uncontrolled asthma.My cancer is advanced or has spread, tests positive for EGFR, and has not improved with standard treatments.I have never been treated with anti-PD-(L)1 therapy.I have Stage IIIB cancer and cannot undergo curative surgery or radiotherapy.My lung cancer is at an advanced stage and has been tested positive for EGFR.My cancer returned or worsened after initial treatment with specific immune and chemotherapy drugs.I am willing to undergo two biopsies for the study.I have a tumor that can be biopsied for this study.I know my cancer's mutation status and have tried or can't try standard treatments.I am 18 years old or older.My brain metastases are stable, treated, and I don't need steroids.My cancer progressed after treatment with platinum-based chemo and anti-PD-(L)1 drugs.I haven't had cancer other than skin, low-grade prostate, or cervical in situ in the last 3 years.I have or had lung scarring or interstitial lung disease.I have mild side effects from previous treatments, but hair loss, hormone issues, or mild nerve pain is okay.I haven't had cancer treatments, major surgery, or used investigational drugs in the last 28 days.I have had anti-PD-(L)1 therapy without severe side effects.My cancer has returned or spread, is in my head or neck, and tests show it has EGFR.
- Group 1: Monotherapy DF9001 Dose Escalation
- Group 2: Monotherapy DF9001 PK/PD Expansion
- Group 3: Monotherapy DF9001 Expansion in Head and Neck Squamous Cell Carcinoma
- Group 4: Monotherapy DF9001 Expansion in Colorectal Cancer
- Group 5: Monotherapy DF9001 Expansion in Non-small Cell Lung Cancer
- Group 6: Combination PK/PD Expansion with DF9001 and nivolumab
- Group 7: Combination Expansion of DF9001 and nivolumab in Head and Neck Squamous Cell Carcinoma
- Group 8: Combination Expansion of DF9001 and nivolumab in Colorectal Cancer
- Group 9: Combination Expansion of DF9001 and nivolumab in Non-Small Cell Lung Cancer
- Group 10: Combination Escalation with DF9001 and nivolumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we still looking for more people to participate in this experiment?
"According to the latest information found on clinicaltrials.gov, this particular trial is not looking for new patients at this time. The posting date was October 1st, 2022 with the most recent update taking place on October 24th, 2022. There are over 2500 other trials that are currently seeking candidates."
What is the primary goal of this research?
"The purpose of this study is to assess the overall response rate in patients receiving DF9001 in combination with nivolumab. Secondary objectives include characterizing the pharmacodynamic profile of DF9001 and measuring changes in immune cell activation, assessing the best overall response by IERC, and determining the number, severity, and duration of treatment-related adverse events according to NCI-CTCAE v5.0."
Share this study with friends
Copy Link
Messenger